Global health perspectives on antibacterial drug discovery and the preclinical pipeline

Antibacterial resistance is a global issue requiring international cooperation. Current clinical pipelines mainly consist of antibiotic derivatives, while the discovery and preclinical pipeline includes new direct-acting agents targeting various pathways. These agents could address infections worldwide, benefiting large patient populations. However, the pipeline is insufficiently robust to offset high attrition rates and meet global health needs.